SEC Tracker
Get the app

AbCellera Biologics ABCL

AbCellera reports Q3 2026 results

AbCellera Biologics (ABCL) filed an 8-K with the SEC on Nov 9, 2026, 4:22 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results, Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Major
  1. Net loss of $40.8 million, down from $57.1 million in Q3 2025
  2. Raised $200 million, bringing liquidity to $900 million
  3. Positive Phase 2 results for ABCL635, leading to late-stage development in 2027

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when AbCellera Biologics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.